Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2013

View Archived Issues

Molecular InSight Pharmaceuticals prepares novel rhenium complexes

U.S. team discovers new monoacylglycerol lipase inhibitors

Reversal of apixaban anticoagulation with PRT-064445 in phase II study detailed

Transition Therapeutics licenses candidate for osteoarthritis pain from Lilly

Enrollment begins in phase II LGX-818 melanoma trial

FDA approves use of Hologic's Aptima HPV assay on fully automated Panther system

New Alzheimer's disease model is based on N-truncated Abeta4-42 expression

FDA accepts for review Merck & Co.'s vorapaxar NDA for secondary complications

Sarepta plans eteplirsen NDA submission

NOXXON's phase IIa study in diabetic nephropathy now fully enrolled

Reversal of oral anticoagulant activity with PER-977 described

Galectin begins dosing in phase I trial of GR-MD-02

Questcor to commence screening for phase II study of H.P. Acthar Gel in ALS

FDA grants orphan drug designation to Verastem's defactinib in mesothelioma

Fred Hutchinson Cancer Research Center receives National Cancer Institute grant

FDA advisory committee votes in favor of Cimzia for active axial spondyloarthritis

Northeastern University discloses new CB1 receptor modulators

Valproic acid analogue evaluated for antimigraine potential

InhibOx receives grant to develop novel therapies for multidrug-resistant infections

Allergan prepares new sodium channel blockers

Researchers at Complix patent novel polypeptides for cancer

Health Canada approves two GSK drugs for metastatic melanoma

Akebia Therapeutics commences phase IIb trial of oral HIF-PH inhibitor for anemia

New agents for tuberculosis synthesized by CSIR

Scientists at BioAlliance divulge new murine/human antibodies targeting TfR

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...